| Title: |
Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France |
| Authors: |
Pugliese, Pascal; Joly, Valentin; Valantin, Marc-Antoine; Cotte, Laurent; Huleux, Thomas; Allavena, Clotilde; Reynes, Jacques; Poizot-Martin, Isabelle; Bani-Sadr, Firouzé; Cuzin, Lise; Brégigeon, S.; Faucher, O.; Orticoni, M.; Soavi, M.J.; Geneau de Lamarlière, P.; Laroche, H.; Ressiot, E.; Carta, M.; Ducassou, M.J.; Jacquet, I.; Gallie, S.; Galinier, A.; Ritleng, A.S.; Ivanova, A.; Blanco-Betancourt, C.; Lions, C.; Debreux, C.; Obry-Roguet, V.; Alvarez, M.; Biezunski, N.; Debard, A.; Delobel, P.; Delpierre, C.; Garipuy, D.; Lansalot, P.; Lelievre, L.; Lepain, I.; Marcel, M.; Marchou, B.; Martin-Blondel, G.; Metsu, D.; Mularczyk, M.; Porte, L.; Puntis, E.; Saune, K.; Ceppi, C.; Cua, E.; Cottalorda, J.; Dellamonica, P.; Demonchy, E.; Dunais, B.; Durant, J.; Etienne, C.; Ferrando, S.; G. Fuzibet, J.; Garraffo, R.; Risso, K.; Mondain, V.; Naqvi, A.; Oran, N.; Perbost, I.; Pillet, S.; Prouvost-Keller, B.; Pradier, C.; Wehrlen-Pugliese, S.; Rosenthal, E.; Sausse, S.; Roger, P.M.; Bernaud, C.; Billaud, E.; Biron, C.; Bonnet, B.; Bouchez, S.; Boutoille, D.; Brunet-Cartier, C.; Hall, N.; Jovelin, T.; Morineau, P.; Raffi, F.; Reliquet, V.; Hue, H.; Larmet, L.; Pineau, So.; Ferré, V.; André-Garnier, E.; Rodallec, A.; Vivrel, F.; Lefebvre, M.; Grossi, O.; Point, P.; Aubry, O.; Ajana, F.; Aissi, E.; Alcaraz, I.; Baclet, V.; Choisy, P.; Huleux, T.; Melliez, H.; Meybeck, A.; Pasquet, A.; Riff, B.; Robineau, O.; Valette, M.; Viget, N.; Yazdanpanah, Yazdan; Landman, R.; Duvivier, Claudine; Agher, R.; Katlama, C.; Lortholary, O.; Lanternier, F.; Charlier, C.; Rouzaud, C.; Henry, B.; Avettand-Fenoel, V.; Rouzioux, C.; Consigny, P.H.; Cessot, G.; Touam, F.; Usubillaga, R.; Louisin, C.; Cabié, A.; Abel, S.; Pierre-François, S.; Pircher, Mathilde; Rozé, B.; Rey, D.; Fischer, P.; Partisani, M.; Cheneau, C.; Priester, M.; Batard, Ml.; Bernard-Henry, C.; de Mautort, E.; Chirouze, C.; Drobacheff-Thiébaut, C.; Faller, J.P.; Faucher, J.F.; Foltzer, A.; Gil, H.; Hustache-Mathieu, L.; Hoen, B.; Jacomet, C.; Laurichesse, H.; Lesens, O.; Vidal, M.; Mrozek, N.; Aumeran, Claire; Baud, O.; Beytout, J.; Coban, D.; Casanova, S.; Rouger, C.; Berger, J.L.; N’guyen, Y.; Lambert, D.; Kmiec, I.; Hentzien, M.; Chidiac, C.; Ader, F.; Biron, F.; Boibieux, A.; Ferry, T.; Miailhes, P; Perpoint, T.; Valour, F.; Degroodt, S. |
| Contributors: |
Service d'infectiologie CHU Nice; Centre Hospitalier Universitaire de Nice (CHU Nice); AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)); Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Hôpital de la Croix-Rousse CHU - HCL; Hospices Civils de Lyon (HCL); Centre Hospitalier Gustave Dron Tourcoing; Service de maladies infectieuses et tropicales Nantes; Université de Nantes (UN)-Hôtel-Dieu-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI); Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I (UY1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Cheikh Anta Diop de Dakar Sénégal (UCAD); Hôpital Sainte-Marguerite CHU - APHM (Hôpitaux Sud); Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD); Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM); Hôpital universitaire Robert Debré Reims (CHU Reims); SFR CAP Santé (Champagne-Ardenne Picardie Santé); Université de Reims Champagne-Ardenne (URCA); Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP); Université Toulouse III - Paul Sabatier (UT3); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Service d'Immuno-hématologie clinique Hôpital Sainte Marguerite - APHM; Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite CHU - APHM (Hôpitaux Sud); Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); Services de Maladies Infectieuses et Tropicales CHU Bichat; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre d'infectiologie Necker-Pasteur CHU Necker; Institut Pasteur Paris (IP)-Hôpital Necker - Enfants Malades AP-HP; Centre Hospitalier Universitaire de Martinique Fort-de-France, Martinique (CHU de Martinique); Hôpitaux Universitaires de Strasbourg (HUS); Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon); CHU Pointe-à-Pitre / Abymes Guadeloupe; CHU Clermont-Ferrand; Dat’AIDS group |
| Source: |
ISSN: 0399-077X. |
| Publisher Information: |
CCSD; Elsevier Masson |
| Publication Year: |
2019 |
| Collection: |
Université Toulouse III - Paul Sabatier: HAL-UPS |
| Subject Terms: |
Traitement antirétroviral initial; Integrase strand transfer inhibitors; Initial HIV therapy; Inhibiteurs d’intégrase; Infection par le VIH; HIV infection; [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology; [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology; [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology |
| Description: |
International audience ; OBJECTIVE:To describe the changes in first-line antiretroviral (ART) regimens in France between 2005 and 2015 and patients' characteristics related to the use of protease inhibitors in 2015.METHODS:We extracted all patients starting ART between 2005 and 2015 from a large prospective cohort. Regimens were classified as three nucleoside reverse transcriptase inhibitors (NRTI), or two NRTIs with a boosted protease inhibitor (bPI), with a non-nucleoside reverse transcriptase inhibitor (NNRTI), or with an INSTI. Patients' characteristics at the time of initiation were collected. A multinomial logit model was fitted to analyze characteristics related to the choice of regimen in 2015.RESULTS:We analyzed data from 15,897 patients. The proportion of patients starting with (i) a bPI decreased from 60% before 2014 to 38.1% in 2015; (ii) an NNRTI decreased from 30% to 17.8% in 2015; (iii) an INSTI gradually increased to 39.4% in 2015. In 2015, patients with an initial viral load ˃5 log copies/mL were less likely to receive NNRTI (OR=0.08) or INSTI regimens (OR=0.69) than bPIs. Patients with initial CD4+ T cell count ˂200/mm3 were less likely to receive an NNRTI (OR=0.28) or an INSTI regimen (OR=0.52) than a bPI. Women were less likely to receive an NNRTI (OR=0.79) or an INSTI regimen (OR=0.71) than a bPI; although this depended on age.CONCLUSION:The use of bPI as first-line ART declined sharply in France from 2005 to 2015. bPI remained of preferential use in patients with high viral load, low CD4+ T cell count, and in women. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/30409541; PUBMED: 30409541 |
| DOI: |
10.1016/j.medmal.2018.10.005 |
| Availability: |
https://univ-reims.hal.science/hal-03261312; https://univ-reims.hal.science/hal-03261312v1/document; https://univ-reims.hal.science/hal-03261312v1/file/S0399077X17305449.pdf; https://doi.org/10.1016/j.medmal.2018.10.005 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.DDBD5EE9 |
| Database: |
BASE |